Literature DB >> 18200610

Establishment of a pharmacoepidemiological database in Germany: methodological potential, scientific value and practical limitations.

Iris Pigeot1, Wolfgang Ahrens.   

Abstract

PURPOSE: We present a new population-based pharmacoepidemiological (PE) database obtained from statutory health insurances (SHIs) that is able to generate signals, to monitor prescribed drugs and to describe drug utilisation. We discuss methodological features of the database and we assess to which degree this database reflects basic demographic characteristics and hospitalisation rates of the general population.
METHODS: Files of three SHIs were linked with drug dispensation data from a pharmacies' electronic data processing centre on an individual basis using the unique subject identification number (ID) at a trusted third party centre. Plausibility checks and descriptive analyses were carried out.
RESULTS: The database covers 3.6 million SHI-members, provides drug utilisation data and data on hospitalisations. SHI membership is fairly stable over time. Our data indicate marked differences in socio-demographic characteristics between SHIs. Hospital admission rates standardised for age vary between 0.164 and 0.229 per person year, which is in good agreement with official statistics (0.20). The age distribution shows good agreement for men and some underrepresentation for women above the age of 60 as compared to the general population.
CONCLUSIONS: Confounder information on medical conditions, concomitant medications and socio-demographic variables can be obtained from the database, while the assessment of confounders related to lifestyle requires supplementary data collection. The database allows for a population-based approach and reflects daily practice including off-label use of drugs. Independent recording of exposure and outcome data prevents reporting bias on medication or outcome. Legal conditions that allow continuous updating of the database need to be settled. Copyright 2008 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2008        PMID: 18200610     DOI: 10.1002/pds.1545

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  42 in total

1.  High-dimensional versus conventional propensity scores in a comparative effectiveness study of coxibs and reduced upper gastrointestinal complications.

Authors:  E Garbe; S Kloss; M Suling; I Pigeot; S Schneeweiss
Journal:  Eur J Clin Pharmacol       Date:  2012-07-05       Impact factor: 2.953

2.  The Risk of Ischemic Cardio- and Cerebrovascular Events Associated with Oxycodone-Naloxone and Other Extended-Release High-Potency Opioids: A Nested Case-Control Study.

Authors:  Kathrin Jobski; Bianca Kollhorst; Edeltraut Garbe; Tania Schink
Journal:  Drug Saf       Date:  2017-06       Impact factor: 5.606

3.  HPV vaccine uptake after introduction of the vaccine in Germany: an analysis of administrative data.

Authors:  Sabrina Hense; Kathrin Hillebrand; Johannes Horn; Rafael Mikolajczyk; Renate Schulze-Rath; Edeltraut Garbe
Journal:  Hum Vaccin Immunother       Date:  2014-03-17       Impact factor: 3.452

4.  Drug treatment patterns of attention-deficit/hyperactivity disorder in children and adolescents in Germany: results from a large population-based cohort study.

Authors:  Edeltraut Garbe; Rafael T Mikolajczyk; Tobias Banaschewski; Ulrike Petermann; Franz Petermann; Angela A Kraut; Ingo Langner
Journal:  J Child Adolesc Psychopharmacol       Date:  2012-12       Impact factor: 2.576

5.  Drug interactions with phenprocoumon and the risk of serious haemorrhage: a nested case-control study in a large population-based German database.

Authors:  Kathrin Jobski; Sigrid Behr; Edeltraut Garbe
Journal:  Eur J Clin Pharmacol       Date:  2011-03-31       Impact factor: 2.953

6.  The Risk of Opioid Intoxications or Related Events and the Effect of Alcohol-Related Disorders: A Retrospective Cohort Study in German Patients Treated with High-Potency Opioid Analgesics.

Authors:  K Jobski; B Kollhorst; T Schink; Edeltraut Garbe
Journal:  Drug Saf       Date:  2015-09       Impact factor: 5.606

7.  Antidepressant drug use and off-label prescribing in children and adolescents in Germany: results from a large population-based cohort study.

Authors:  Michael Dörks; Ingo Langner; Ulrich Dittmann; Antje Timmer; Edeltraut Garbe
Journal:  Eur Child Adolesc Psychiatry       Date:  2013-03-03       Impact factor: 4.785

8.  Outpatient antipsychotic drug use in children and adolescents in Germany between 2004 and 2011.

Authors:  Carsten Schröder; Michael Dörks; Bianca Kollhorst; Tilo Blenk; Ralf W Dittmann; Edeltraut Garbe; Oliver Riedel
Journal:  Eur Child Adolesc Psychiatry       Date:  2016-09-13       Impact factor: 4.785

9.  Risk of venous thromboembolism in cancer patients treated with epoetins or blood transfusions.

Authors:  Antonios Douros; Kathrin Jobski; Bianca Kollhorst; Tania Schink; Edeltraut Garbe
Journal:  Br J Clin Pharmacol       Date:  2016-06-22       Impact factor: 4.335

10.  Systemic antibiotic use among children and adolescents in Germany: a population-based study.

Authors:  Jakob Holstiege; Edeltraut Garbe
Journal:  Eur J Pediatr       Date:  2013-02-10       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.